Clinical Trial Update: Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of Topical R333 in patients with discoid lupus erythematosus and systemic lupus erythematosus lesions has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Discoid Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• Topical R333

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic | Phase 2 | Status: COMPLETED | Results posted: 2016-06-08